Physician profile
Daniela Ciltea
NPI 1518186360
$14,505.83
in general payments reported to CMS, 2019-2025
23 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $127 · 2021: $746 · 2022: $13K · 2023: $16.67 · 2024: $112 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $262.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $13,115.73 | 2021-2025 | |
| Novo Nordisk INC | $399.59 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $207.23 | 2020-2024 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $121.84 | 2021 | |
| Merck Sharp & Dohme LLC | $110.40 | 2019 | |
| Amarin Pharma, INC. | $64.37 | 2020-2021 | |
| Abbvie INC. | $61.42 | 2019 | |
| Corcept Therapeutics | $55.03 | 2021-2024 | Korlym |
| Astrazeneca Pharmaceuticals Lp | $44.89 | 2020-2021 | |
| Insulet Corporation | $40.14 | 2019-2024 | Omnipod |
| Medtronic Minimed, INC. | $38.89 | 2020 | |
| Dexcom, INC. | $37.09 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.90 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $27.71 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.81 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $21.62 | 2019 | |
| Clarus Therapeutics INC. | $21.48 | 2021 | |
| Pfizer INC. | $13.19 | 2019 | |
| Abbott Laboratories | $13.12 | 2020 | |
| Esperion Therapeutics, INC. | $12.90 | 2021 | |
| Gilead Sciences, INC. | $12.65 | 2019 | |
| Antares Pharma, INC. | $12.50 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Ciltea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.